Abstract
The highly toxic Aβ(25–35) is a peculiar peptide that differs from all the other commonly studied β-amyloid peptides because of its extremely rapid aggregation properties and enhanced neurotoxicity. We investigated Aβ(25–35) aggregation in H2O at pH 3.0 and at pH 7.4 by means of in-solution analyses. Adopting UV spectroscopy, Congo red spectrophotometry and thioflavin T fluorimetry, we were able to quantify, in water, the very fast assembling time necessary for Aβ(25–35) to form stable insoluble aggregates and their ability to seed or not seed fibril growth. Our quantitative results, which confirm a very rapid assembly leading to stable insoluble aggregates of Aβ(25–35) only when incubated at pH 7.4, might be helpful for designing novel aggregation inhibitors and to shed light on the in vivo environment in which fibril formation takes place.
Similar content being viewed by others
Abbreviations
- AD:
-
Alzheimer disease
- DMSO:
-
dimethyl sulphoxide
- HFIP:
-
hexafluorisopropanol
- IBM:
-
inclusion body myositis
- NCC:
-
nucleated conformational conversion’
- OD:
-
optical density
- PBS:
-
phosphate buffered saline
- pI:
-
isoelectric point
- SDS:
-
sodium dodecyl sulphate
- TFA:
-
trifluoroacetic acid
- Th-T:
-
thioflavin-T
References
Baglioni S, Casamenti F, Bucciantini M, Luheshi L M, Taddei N, Chiti F, Dobson C M and Stefani M 2006 Prefibrillar amyloid aggregates could be generic toxins in higher organisms; J. Neurosci. 26 8160–8167
Ban J Y, Nguyen H T, Lee H J, Cho S O, Ju H S, Kim J Y, Bae K, Song K S and Seong Y H 2008 Neuroprotective properties of gallic acid from Sanguisorbae radix on amyloid beta protein (25–35)-induced toxicity in cultured rat cortical neurons; Biol. Pharm. Bull. 31 149–153
Ban T, Hamada D, Hasegawa K, Naiki H and Goto Y 2003 Direct observation of amyloid fibril growth monitored by Th-T fluorescence; J. Biol. Chem. 278 16462–16465
Bieschke J, Siegel SJ, Fu Y and Kelly JW 2008 Alzheimer’s abeta peptides containing an isostructural backbone mutation afford distinct aggregate morphologies but analogous cytotoxicity. Evidence for a common low-abundance toxic structure(s); Biochemistry 47 50–59
Bitan G and Teplow D B 2005 Preparation of aggregate-free, low molecular weight amyloid-beta for assembly and toxicity assays; Methods Mol. Biol. 299 3–9
Bradford M M 1976 A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding; Anal. Biochem. 72 248–254
Burdick D, Soreghan B, Kwon M, Kosmoski J, Knauer M, Henschen A, Yates J, Cotman C and Glabe C 1992 Assembly and aggregation properties of synthetic Alzheimer’s A4/b amyloid peptide analogs; J. Biol. Chem. 267 546–554
Calamai M, Chiti F and Dobson C M 2005 Amyloid fibril formation can proceed from different conformations of a partially unfolded protein; Biophys. J. 89 4201–4210
Carrotta R, Manno M, Bulone D, Martorana V, and San Biagio P L 2005 Protofibril formation of amyloid β-protein at low pH via a non-cooperative elongation mechanism; J. Biol. Chem. 280 30001–30008
Clementi M E, Marini S, Coletta M, Orsini F, Giardina B and Misiti F 2005 Aβ(31–35) and Aβ(25–35) fragments of amyloid β-protein induce cellular death through apoptotic signals: role of the redox state of methionine-35; FEBS Lett. 579 2913–2918
Collins S R, Douglass A, Vale R D and Weissman J S 2004 Mechanism of prion propagation: amyloid growth occurs by monomer addition; PLoS Biol. 2 e321
Dobson C M 2006 Protein aggregation and its consequences for human disease; Protein Pept. Lett. 13 219–227
D’Ursi A M, Armenante M R, Guerrini R, Salvadori S, Sorrentino G and Picone D 2004 Solution structure of amyloid beta-peptide (25–35) in different media; J. Med. Chem. 12 4231–4238
Eisert R, Felau L and Brown L R 2006 Methods for enhancing the accuracy and reproducibility of Congo Red and Th-T assays; Anal. Biochem. 353 144–146
Gazit E 2005 Mechanisms of amyloid fibril self-assembly and inhibition. Model short peptides as a key research tool; FEBS J. 272 5971–5978
Hölscher C 2005 Development of beta-amyloid-induced neurodegeneration in Alzheimer’s disease and novel neuro-protective strategies; Rev. Neurosci. 16 181–212
Holscher C, Gengler S, Gault V A, Harriott P and Mallot H A 2007 Soluble beta-amyloid(25–35) reversibly impairs hippocampal synaptic plasticity and spatial learning; Eur. J. Pharmacol. 561 85–90
Jayaraman M, Kannayiram G and Rajadas J 2008 Amyloid toxicity in skeletal myoblasts: implications for inclusion-body myositis; Arch. Biochem. Biophys. 474 15–21
Klunk W E, Pettegrew J V and Abrham D J 1998 Quantitative evaluation of Congo Red binding to amyloid-like proteins with a beta-pleated sheet conformation; J. Histochem. Cytochem. 37 1273–1281
Korczyn A D 2008 The amyloid cascade hypothesis; Alzheimers Dement. 4 176–178
Kubo T, Nishimura S, Kumagae Y and Kaneko Y 2002 In vivo conversion of racemized beta-amyloid ((D-Ser 26)A beta 1–40) to truncated and toxic fragments ((D-Ser 26)A beta 25-35/40) and fragment presence in the brains of Alzheimer’s patients; J. Neurosci. Res. 70 474–483
LeVine H 3rd 1997 Stopped-flow kinetics reveal multiple phase of Th-T binding to Alzheimer β(1–40) amyloid fibrils; Arch. Biochem. Biophys. 342 306–316
LeVine H 2004 Alzheimer’s beta-peptide oligomer formation at physiologic concentrations; Anal. Biochem. 335 81–90
Maurice T, Lockhart B P and Privat A 1996 Amnesia induced in mice by centrally administered β-amyloid peptides involves cholinergic dysfunction; Brain Res. 706 181
Meinke J H and Hansmann U H 2007 Aggregation of beta-amyloid fragments; J. Chem. Phys. 126 014706
Misiti F, Sampaolese B, Pezzotti M, Marini S, Coletta M, Ceccarelli L, Giardina B and Clementi M E 2005 Aβ(31–35) peptide induces apoptosis in pc 12 cells: contrast with Aβ (25–35) peptide and examination of underlying mechanisms; Neurochem. Int. 46 575–583
Nesgaard L, Vad B, Christiansen G and Otzen D 2009 Kinetic partitioning between aggregation and vesicle permeabilization by modified ADan; Biochim. Biophys. Acta 1794 84–93
Petkova A T, Leapman R D, Guo Z, Yau W M, Mattson M P and Tycko R 2005 Self-propagating, molecular-level polymorphism in Alzheimer’s beta-amyloid fibrils; Science 307 262–265
Pike C J, Burdick D, Walencewicz A Z, Glabe C G and Cotman C W 1993 Neurodegeneration induced by beta-amyloid peptides in vitro: the role of peptide assembly state; J. Neurosci. 13 1676–1687
Pike C J, Walencewicz-Wasserman A J, Kosmoski J, Cribbs D H, Glabe C G and Cotman C W 1995 Structure-activity analyses of β-amyloid peptides: contributions of the β 25–35 region to aggregation and neurotoxicity; J. Neurochem. 64 253–265
Platt G W, McParland V J, Kalverda A P, Homans S W and Radford S E 2005 Dynamics in the unfolded state of beta2-microglobulin studied by NMR; J. Mol. Biol. 346 279–294
Roychaudhuri R, Yang M, Hoshi M M and Teplow D B 2008 Amyloid beta-protein assembly and Alzheimer’s disease; J. Biol. Chem. 8 4749–4753
Serio T R, Cashikar A G, Kowal A S, Sawicki G J, Moslehi J J, Serpell L, Amsdorf M F and Lindquist S L 2000 Nucleated conformational conversion and the replication of conformational information by a prion determinant; Science 289 1317–1321
Simmons L K, May P C, Tomaselli K J, Rydel R E, Fuson K S, Brigham E F, Wright S, Lieberburg I, Becker G W and Brems D N 1994 Secondary structure of amyloid beta peptide correlates with neurotoxic activity in vitro; Mol. Pharmacol. 45 373–379
Smith A M, Jahn T R, Ashcroft A E and Radford S E 2006 Direct observation of oligomeric species formed in the early stages of amyloid fibril formation using electrospray ionisation mass spectrometry; J. Mol. Biol. 364 9–19
Snyder S W, Ladror U S, Wade W S, Wang G T, Barrett L W, Matayoshi E D, Huffaker H J, Krafft G A and Holzman T F 1994 Amyloid-β aggregation: selective inhibition in mixtures of amyloid with different chain lengths; Biophys. J. 67 1216–1228
Stefani M 2007 Generic cell dysfunction in neurodegenerative disorders: role of surfaces in early protein misfolding, aggregation, and aggregate cytotoxicity; Neuroscientist 13 519–531
Takadera T, Sakura N, Mohri T and Hashimoto T 1993 Toxic effect of a beta-amyloid peptide (beta 22–35) on the hippocampal neuron and its prevention; Neurosci. Lett. 161 41–44
Walsh D M and Selkoe D J 2004 Oligomers on the brain: the emerging role of soluble protein aggregates in neurodegeneration; Protein Pept. Lett. 11 213–228
Wang S, Chang Y, Chen P and Liu K 2004 A kinetic study on the aggregation behavior of β-amyloid peptides in different initial solvent environments; Biochem. Eng. J. 29 129–138
Wei G and Shea G E 2006 Effects of solvent on the structure of the Alzheimer amyloid-beta(25–35) peptide; Biophys. J. 91 1638–1647
Wood S J, Maleeff B, Hart T and Wetzel R 1996 Physical, morphological and functional differences between pH 5.8 and 7.4 aggregates of the Alzheimers amyloid peptide Aβ; J. Mol. Biol. 256 870–877
Yoshiike Y, Tanemura K, Murayama O, Akagi T, Murayama M, Sato S, Sun X, Tanaka N and Takashima A 2001 New insights on how metals disrupt amyloid beta-aggregation and their effects on amyloid-beta cytotoxicity; J. Biol. Chem. 276 32293–32299
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Millucci, L., Raggiaschi, R., Franceschini, D. et al. Rapid aggregation and assembly in aqueous solution of Aβ (25–35) peptide. J Biosci 34, 293–303 (2009). https://doi.org/10.1007/s12038-009-0033-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12038-009-0033-3